Pharmaceuticals Novartis holds out prospect of further growth at Investor Day
Novartis reaffirms its own growth targets at its Investor Day. The pharmaceutical company is relying on a well-filled pipeline with promising product candidates.
20.11.2025, 07:49
SDA
Novartis expects to increase sales by 5 to 6 percent annually between 2025 and 2030. The Basel-based company reformulated these medium-term targets on Thursday.
Meanwhile, the company has confirmed its previous medium-term guidance. For 2024 to 2029, Novartis remains committed to increasing revenue by 6 percent annually. Novartis had only increased this assumption from 5% to 6% at the end of October following the acquisition of Avidity Biosciences for USD 12 billion.
Well-filled pipeline
This growth is to be based on successful existing drugs as well as numerous new products. These could come onto the market in the coming years.
Novartis considers eight drugs to be particularly promising, each with a sales potential of three to ten billion US dollars. These include the cancer drugs Kisqali and Scemblix, for which Novartis has even increased the expected peak sales potential.
At the same time, Novartis is confident about its own development pipeline: More than 30 new drugs with high value potential are in the pipeline. In the next two years, more than 15 important study results should be available that are decisive for possible approvals.
Many of the future products will also be patent-protected in the USA until well into the 2030s - an important factor for long-term growth.
Equipped for growth
Novartis also confirms its recent statements on profitability. With a core operating profit margin of 41.2% after the first nine months, the Group has achieved its own targets two years earlier than expected. However, in the course of the Avidity takeover at the end of October, the management announced that this was likely to be somewhat lower in the short term. From 2029, however, it should be back above the 40 percent mark.
CEO Vas Narasimhan emphasized in the press release that Novartis is well positioned for the future thanks to targeted acquisitions and investments in research and development: "We have a strong foundation today and a pipeline that will enable us to grow well beyond 2030."
